Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 24, 2026

The BioPharm Brief: Reviews, Deals, and Delays

Listen
0:00 / 0:00

Today’s BioPharm Brief covers FDA priority review for GSK’s Jemperli in locally advanced rectal cancer, Genentech’s $2.3 billion deal for Hanmi’s investigational obesity drug, and an extended FDA review of Capricor’s deramiocel for Duchenne muscular dystrophy.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here’s what we’re talking about today.

GSK’s Jemperli is headed for an FDA priority review in a new rectal cancer indication. The agency accepted a supplemental Biologics License Application for dostarlimab in previously untreated stage II and III mismatch repair-deficient, or dMMR, microsatellite instability-high, or MSI-H, locally advanced rectal cancer. The application is supported by Phase 2 AZUR-1 data showing sustained clinical complete responses with Jemperli monotherapy. If approved, GSK says Jemperli could become the first immunotherapy option that allows some patients to avoid or delay chemotherapy, radiation, and surgery. The FDA has set a February 2027 PDUFA date, although the application is also eligible for the National Priority Voucher program, which could potentially accelerate the decision.

In obesity, Genentech is making a major bet on a treatment designed to address one of the challenges associated with current weight-loss therapies. Hanmi Pharmaceutical has licensed global rights, excluding South Korea, to HM17321 in a deal valued at up to $2.3 billion. The investigational drug is a selective CRFR2 agonist based on a urocortin-2 analog, rather than a GLP-1-based mechanism, and is designed to promote weight loss while preserving lean mass. Hanmi will complete Phase 1, with Genentech taking over from phase 2 onward. The deal includes $190 million upfront, with the remainder tied to development, regulatory, and commercial milestones, plus tiered royalties.

And Capricor Therapeutics is getting more time to make its case for deramiocel in Duchenne muscular dystrophy. The FDA extended the PDUFA date for the cell therapy from August 22 to November 22 after Capricor submitted an amendment containing 24-month open-label extension data from the HOPE-3 study, along with additional analyses. The amendment follows a July FDA advisory committee meeting in which reviewers questioned Capricor’s interpretation of the trial’s efficacy results. The company is seeking approval under a refined indication focused on upper limb function, an important measure of independence for patients with progressive DMD.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • GSK’s Jemperli is headed for priority review in dMMR/MSI-H locally advanced rectal cancer.
  • Genentech is betting up to $2.3 billion on Hanmi’s next-generation obesity drug HM17321.
  • Capricor’s deramiocel review has been extended to November as the FDA considers additional DMD data.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more